In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

Wiley - Tập 83 Số 6 - Trang 563-567 - 1992
Yoshihiro SUGIYAMA1, Miki Aihara1, Masafumi Shibamori1, Kyohei Deguchi1, Kenichi Imagawa1, Mikio Kikuchi1, Hiroshi Momota2, Takachika Azuma3, Hidechika Okada3, Özge Alper4, Jiro Hitomi4, Ken Yamaguchi4
1Viral Diseases Research Division, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., 463‐10 Kagasuno, Kawaucki‐cho, Tokushima 771‐01
2Cell Engineering Division, Bioscience Laboratory, Earth Chemical Co., Ltd., 1122‐73 Kitamachi, Nishihama, Ako‐shi, Hyogo 678‐02
3Department of Molecular Biology, Nagoya City University School of Medicine, Mizuhocho, Mizuho-ku, Nagoya 467
4Growth Factor Division, National Cancer Center Research Institute, Tsukiji 5‐1‐1, Chuo‐ku, Tokyo 104

Tóm tắt

With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti‐tumor activity in vitro on a breast tumor cell line, ZR‐75–1, which expressed abundant c‐erbB‐2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.

Từ khóa


Tài liệu tham khảo

Martin J. S. D., 1989, Effect of CAMPATH‐1 antibodies in vivo in patients with lymphoid malignancies. Influence of antibody isotype, Blood, 73, 1431, 10.1182/blood.V73.6.1431.1431

10.1073/pnas.83.22.8694

10.1126/science.3925553

10.1002/ijc.2910410422

10.1007/BF01744944

Oshimi K., 1991, Increased lysis of patient CD 10–positive leukemic cells by T cells coated with anti‐CD3 Fab′ antibody cross‐linked to anti‐CD10 Fab′ antibody, Blood, 77, 1044, 10.1182/blood.V77.5.1044.1044

10.1002/eji.1830190814

10.1016/0140-6736(90)90205-J

Leij L., 1990, Bispecific Antibodies and Targeted Cellular Cytotoxicity, 249

10.1038/319230a0

Alper Ö., 1990, The presence of c‐erbB‐2 gene product‐related protein in culture medium conditioned by breast cancer cell line SK‐BR‐3, Cell Growth Differ., 1, 591

10.1002/eji.1830110412

10.1038/305537a0

10.1002/eji.1830190814

10.1016/0022-1759(83)90415-5

10.1002/j.1460-2075.1987.tb04797.x

)Okada H. Motnota H. Azuma T. Toshio H.andOkada N.Specific cytolysis of HIV‐infected cells by lymphocytes armed with bifunctional antibodies.Immunol Lett. in press .

Matsushita S., 1988, Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope, J. Virol, 62, 2107, 10.1128/jvi.62.6.2107-2114.1988

10.1073/pnas.84.20.7159

10.1002/ijc.2910450314

Mori K., 1989, C‐erbB‐2 gene product, a membrane protein commonly expressed on human fetal epithelial cells, Lab. Invest., 61, 93

Paterson M. C., 1991, Correlation between c‐erbB‐2 amplification and risk of recurrent disease in node negative breast cancer, Cancer Res., 51, 556

McCann A. H., 1991, Prognostic significance of c‐erbB‐2 and estrogen receptor status in human breast cancer, Cancer Res., 51, 3296

10.1126/science.2470152

Nishimura T., 1992, Human c‐erbB‐2 proto‐oncogene product as a target for bispecific antibody‐directed adoptive tumor immunotherapy, Int. J. Cancer, 51, 1

Thông tin
Thông tin xuất bản

Wiley

Tập 83 Số 6

563-567

Thông tin tác giả